Your browser is no longer supported. Please, upgrade your browser.
Settings
ALXN Alexion Pharmaceuticals, Inc. daily Stock Chart
ALXN [NASD]
Alexion Pharmaceuticals, Inc.
IndexS&P 500 P/E68.33 EPS (ttm)1.76 Insider Own0.30% Shs Outstand224.61M Perf Week-1.76%
Market Cap27.01B Forward P/E17.95 EPS next Y6.70 Insider Trans-18.47% Shs Float223.81M Perf Month-8.08%
Income399.00M PEG3.69 EPS next Q1.24 Inst Own99.50% Short Float1.61% Perf Quarter3.03%
Sales3.08B P/S8.76 EPS this Y162.90% Inst Trans1.73% Short Ratio1.68 Perf Half Y-7.75%
Book/sh39.05 P/B3.08 EPS next Y27.64% ROA3.00% Target Price161.55 Perf Year-10.01%
Cash/sh5.76 P/C20.89 EPS next 5Y18.54% ROE4.80% 52W Range109.12 - 162.00 Perf YTD-1.71%
Dividend- P/FCF35.87 EPS past 5Y14.00% ROI4.20% 52W High-26.44% Beta1.33
Dividend %- Quick Ratio2.70 Sales past 5Y31.50% Gross Margin91.60% 52W Low9.20% ATR2.98
Employees3121 Current Ratio3.10 Sales Q/Q18.50% Oper. Margin21.60% RSI (14)32.73 Volatility2.13% 2.23%
OptionableYes Debt/Eq0.35 EPS Q/Q38.80% Profit Margin12.90% Rel Volume0.52 Prev Close120.26
ShortableYes LT Debt/Eq0.33 EarningsFeb 16 BMO Payout0.00% Avg Volume2.14M Price119.16
Recom1.90 SMA20-5.92% SMA50-7.65% SMA200-5.96% Volume1,071,371 Change-0.91%
Mar-02-17Initiated Instinet Buy $148
Feb-17-17Reiterated RBC Capital Mkts Outperform $187 → $177
Dec-22-16Reiterated RBC Capital Mkts Outperform $188 → $187
Dec-15-16Initiated Oppenheimer Perform
Dec-13-16Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-03-16Initiated Deutsche Bank Buy $164
Oct-28-16Upgrade Goldman Neutral → Buy
Oct-28-16Upgrade FBR & Co. Underperform → Mkt Perform $92 → $130
Oct-28-16Reiterated Wedbush Neutral $132 → $135
Sep-23-16Initiated Wedbush Neutral $132
Sep-16-16Reiterated FBR & Co. Underperform $82 → $92
Sep-15-16Initiated FBR & Co. Underperform $82
Jul-29-16Reiterated Stifel Buy $195 → $182
Jul-29-16Reiterated Barclays Equal Weight $165 → $150
Jul-13-16Reiterated SunTrust Buy $220 → $197
Jul-13-16Initiated RBC Capital Mkts Outperform $188
Jul-11-16Upgrade Credit Suisse Neutral → Outperform $186 → $165
Jun-27-16Upgrade Citigroup Neutral → Buy
May-09-16Reiterated Barclays Equal Weight $175 → $180
Mar-08-16Downgrade Robert W. Baird Outperform → Neutral $221 → $170
Mar-24-17 09:02AM  Omeros: Power in the Pipeline at Motley Fool
Mar-23-17 10:16AM  Alexion (ALXN) Files for Soliris' Label Expansion in Japan
09:36AM  Biotech Premarket Movers: Insys, Ultragenyx, Alexion
Mar-22-17 04:05PM  Alexion Submits Application in Japan for Soliris® (Eculizumab) as a Potential Treatment for Patients with Refractory Generalized Myasthenia Gravis (gMG) Business Wire
Mar-17-17 06:01PM  Alexion (ALXN) Licenses Artubus Technology for Rare Diseases
11:43AM  Alexion Buys LNP Drug Delivery Tech from Arbutus at Investopedia
Mar-16-17 05:00PM  Arbutus Licenses LNP Delivery Technology to Alexion for Use in Single Messenger RNA Product Candidate GlobeNewswire
Mar-15-17 06:04AM  Pharmaceutical company to lay off more than 200 employees
Mar-14-17 12:55PM  Alexion Trims Workforce, Scraps R&D Programs at Investopedia
09:42AM  Alexion Pharmaceuticals Cuts 7% of Workforce
07:39AM  Why Did the Healthcare Sector Fall on March 13?
01:00AM  England Says No to Drugs That Cost More Than Your Car (or Home)
Mar-13-17 06:17PM  Alexion to cut 7 pct of workforce
04:36PM  Stock market holds its ground as Fed rate decision looms at MarketWatch
Mar-10-17 10:55AM  Alexion's sBLA for Soliris Receives FDA Acknowledgement
Mar-08-17 06:30AM  FDA Accepts sBLA Filing of Soliris® (Eculizumab) as a Potential Treatment for Patients with Refractory Generalized Myasthenia Gravis (gMG) Business Wire
Mar-02-17 04:53PM  ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E
04:05PM  Leonard Bell, M.D., Alexions Founder, Announces Plans to Retire as Chairman and Board Member Business Wire
08:42AM  Coverage initiated on Alexion Pharma by Instinet
Mar-01-17 10:37AM  Regeneron Could See a Modest Rise in Net Profit Margins in 2017
07:36AM  Alexion Expects This to Be Big Medicine in 2017
Feb-28-17 10:36AM  Will Alexions Research Make Gains in the Inhibitor Space?
09:09AM  Alnylam Pharmaceuticals Advances Its Patisiran Research Program
09:07AM  What Alexion Expects from Its Metabolic Disease Drugs in 2017
07:37AM  Understanding Alexions Profit Margin Trend in 2017
Feb-27-17 04:05PM  Alexions Soliris: Gauging Patient Demand
02:35PM  What to Expect from Alexions Revenue in 2017
01:00PM  Inside Alexions Latest Analyst Recommendations
10:21AM  Alexion to Present at Upcoming Investor Conferences Business Wire
Feb-24-17 03:35PM  Inside Vertexs Revenue Expectations for 2017
02:06PM  Vertex Expects Modest Revenue Growth in This
Feb-22-17 01:04PM  ALEXION PHARMACEUTICALS INC Financials
Feb-21-17 12:17PM  Alexion Pharmaceuticals, Inc. :ALXN-US: Earnings Analysis: 2016 By the Numbers : February 21, 2017
Feb-20-17 11:52AM  Alexion Halts Rare-Disease Drug SBC-103 Program at Investopedia
07:52AM  Forget Alexion, Buy these 4 Biotech Stocks Instead
01:48AM  Tough U.K. Line on Rare-Disease Drugs Stirs Concern After Brexit
Feb-19-17 05:15PM  Barron's Picks And Pans: General Motors, Hess, Biotechs And More
Feb-17-17 12:32PM  Alexion Pharmaceuticals, Inc. (ALXN) Suffers Another Blow In The UK at Insider Monkey
09:37AM  Alexion Pharmaceuticals, Inc. :ALXN-US: Earnings Analysis: Q4, 2016 By the Numbers : February 17, 2017
07:44AM  [$$] Takeover Candidate Alexion Is on the Mend at Barrons.com
Feb-16-17 08:57PM  Edited Transcript of ALXN earnings conference call or presentation 16-Feb-17 3:00pm GMT
04:19PM  Alexion (ALXN) Q4 Earnings In-Line, Sales Rise Y/Y
04:16PM  Alexion's 'Meh' 2017 Guide Soothes Worries Of Decline, But PNH Drug Key
04:00PM  Alexion (ALXN) Misses on Q4 Earnings and Revenues
02:30PM  Alexion Needs New Bets
01:31PM  Alexion Pharma's revenue forecast allays investor fears
12:43PM  Alexion 4Q Earnings of $1.26 a Share Beats Street at Investopedia
12:03PM  Alexions Kanuma Drug Denied UK Approval at Investopedia
10:38AM  Alexion Pharma's Bloated Blockbuster Deal Still Haunts
09:30AM  How Alexions Pipeline Is Driving Earnings
09:23AM  Alexion Pharmaceuticals on the Recovery Trail at Investopedia
09:05AM  ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
08:04AM  Early movers: WEN, TIME, ALXN, AVP, GNC, TPX & more at CNBC
07:07AM  Q4 2016 Alexion Pharmaceuticals Inc Earnings Release - Before Market Open
06:48AM  Alexion tops 4Q profit forecasts
06:37AM  Alexion Pharma's revenue rises 18.5 pct
06:30AM  Alexion Reports Fourth Quarter and Full Year 2016 Results and Provides Financial Guidance for 2017 Business Wire
05:59AM  5 Things You Must Know Before the Market Opens Thursday
Feb-15-17 03:30PM  5 Stocks to Watch that Report Earnings Tomorrow
01:50PM  The Top 5 Earnings Coming Out on Thursday
10:59AM  Goldman recommends buying underperformers ahead of their earnings at MarketWatch
08:47AM  Drug Stocks Q4 Earnings Slated for Feb 16: ALXN, ZTS & More
Feb-10-17 05:27PM  Alexion (ALXN) Q4 Earnings: Can the Stock Pull a Surprise?
Feb-08-17 02:01PM  Alexion Pharmaceuticals, Inc. Value Analysis (NASDAQ:ALXN) : February 8, 2017
12:40PM  Alexion's Expensive Bone Drug Gets Restricted By NICE at Investopedia
08:26AM  Oppenheimer: Currency FX on Rx at Barrons.com
Feb-07-17 07:22AM  Alexion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ALXN-US : February 7, 2017
Feb-01-17 03:42PM  More Volatility Ahead for Biotechnology Sector at The Wall Street Journal
Jan-30-17 08:15AM  Blog Coverage EMA's Committee for Medicinal Products for Human Use Provides Positive Opinion for the Marketing Authorization of Amgen's ABP 501 Accesswire
Jan-27-17 07:00AM  Ra Pharma deploys IPO cash in quest to overtake a rare disease rival Alexion at bizjournals.com
Jan-26-17 10:00AM  Alexion Pharmaceuticals to Report Fourth Quarter and Full Year 2016 Results on Thursday, February 16, 2017 Business Wire
Jan-25-17 01:04PM  ALEXION PHARMACEUTICALS INC Financials
Jan-14-17 09:33AM  [$$] Drugmakers alarmed by Trump pricing threat at Financial Times
Jan-13-17 10:50PM  ALEXION 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit against Alexion Pharmaceuticals, Inc. (ALXN) Business Wire
10:10AM  FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alexion Pharmaceuticals, Inc. (ALXN) & Lead Plaintiff Deadline - January 17, 2017 GlobeNewswire
Jan-12-17 05:02PM  EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Alexion Pharmaceuticals, Inc. - ALXN PR Newswire
06:58AM  Trump takes aim at pharma
Jan-11-17 12:36PM  Here Is Why Red-Hot Alexion Is Only Suitable for Risk Takers Now
10:07AM  DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alexion Pharmaceuticals, Inc. (ALXN) and Lead Plaintiff Deadline - January 17, 2017 Accesswire
09:35AM  JPMorgan Makes Big Changes to US Analyst Focus List for January 24/7 Wall St.
08:47AM  Alexion (ALXN) Files for Label Expansion of Soliris in U.S., EU
Jan-10-17 10:45AM  Alexion Seeks Expanded Use for Soliris in US and EU at Investopedia
08:15AM  Blog Coverage Alexion Pharma Applies for US and EU Marketing Approval of Refractory Generalized Myasthenia Gravis Medicine Accesswire
Jan-09-17 05:30PM  Mysterious $5 Billion Biotech Firm Moderna Lays Out Drug Pipeline at Forbes
03:55PM  Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference
03:30PM  Alexion Blood Disorder Meds Wins Orphan Drug Status at Investopedia
02:32PM  Alexion CEO: 'We're moving on' from shakeup
01:33PM  Bullish and Bearish Reversals in the Market
10:42AM  Here's Why Alexion Pharmaceuticals, Inc. Stock Gave Up 36% in 2016 at Motley Fool
10:25AM  Lawsuit for Investors in Shares of Alexion Pharmaceuticals, Inc. (ALXN) Announced by Shareholders Foundation Accesswire
08:15AM  Alexion Blood Disorder Drug Gets Orphan Designation in U.S.
06:30AM  Alexion Submits U.S. and EU Applications Seeking Approval of Soliris® (Eculizumab) as a Treatment for Patients with Refractory Generalized Myasthenia Gravis (gMG) Business Wire
Jan-07-17 05:15PM  INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Alexion Pharmaceuticals, Inc. Limited and Encourages Investors with Losses to Contact the Firm Accesswire
06:00AM  DEADLINE ALERT: Brower Piven Reminds Investors Of The January 17, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess of $100,000 From Investment In Alexion Pharmaceuticals, Inc. To Contact The Firm Business Wire
Jan-06-17 10:50PM  ALEXION SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Alexion Pharmaceuticals, Inc. (ALXN) GlobeNewswire
10:10AM  Company News for January 06, 2017
10:02AM  DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alexion Pharmaceuticals, Inc. (ALXN) and Lead Plaintiff Deadline - January 17, 2017 Accesswire
09:30AM  Alexion: Internal Probe Shows No Revenue Inflation at Investopedia
06:30AM  FDA Grants Orphan Drug Designation to ALXN1210 for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Business Wire
Jan-05-17 04:51PM  3 ideas to improve waiting for your trades +9.50%
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder; and Phase II clinical trials for antibody mediated rejection in presensitized renal transplant patients. Further, it develops cPMP (ALXN 1101) that is in Phase II/III trial for treating metabolic disorders; SBC-103, which is in Phase I/II clinical trials for the treatment of metabolic disorders; ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; and ALXN 1210, which is in Phase I clinical trials to evaluate subcutaneous delivery. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem's proprietary drug discovery engine; and Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for development and commercialization of Moderna's messenger RNA therapeutics to treat rare diseases. The company was founded in 1992 and is headquartered in New Haven, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
O'Neill JulieEVP. Global OperationsMar 02Sale133.8065187,10437,864Mar 06 06:03 PM
Moriarty John BEVP & General CounselMar 01Sale132.5028237,36544,672Mar 01 07:46 PM
MACKAY MARTINEVP & Global Head of R&DMar 01Sale132.5037049,02550,688Mar 01 07:45 PM
BELL LEONARDDirectorMar 01Sale132.501,240164,300390,670Mar 01 07:44 PM
Wagner Heidi LSVP, Global Government AffairsMar 01Sale132.5015620,67029,010Mar 01 07:44 PM
Carmichael ClareEVP, Chief HR OfficerMar 01Sale132.5040453,53039,161Mar 01 07:44 PM
Moriarty John BEVP & General CounselFeb 28Sale131.71910119,85644,954Mar 01 07:46 PM
MACKAY MARTINEVP & Global Head of R&DFeb 28Sale131.7062582,31338,258Mar 01 07:45 PM
Miller EdwardSVP, Chief Compliance OfficerFeb 28Sale131.7033043,46114,884Mar 01 07:45 PM
O'Neill JulieEVP. Global OperationsFeb 28Sale131.7066487,44931,015Mar 01 07:46 PM
BELL LEONARDDirectorFeb 28Sale131.712,738360,622391,910Mar 01 07:44 PM
Wagner Heidi LSVP, Global Government AffairsFeb 28Sale131.7048063,21629,166Mar 01 07:44 PM
Carmichael ClareEVP, Chief HR OfficerFeb 28Sale131.71915120,51533,065Mar 01 07:44 PM
Thiel CarstenEVP, Chief Commercial OfficerFeb 28Sale131.013,783495,61133,860Mar 06 06:03 PM
Moriarty John BEVP & General CounselFeb 27Sale131.2061280,29445,864Mar 01 07:46 PM
Thiel CarstenEVP, Chief Commercial OfficerFeb 27Sale131.20719,31530,197Mar 01 07:45 PM
MACKAY MARTINEVP & Global Head of R&DFeb 27Sale131.20860112,83238,883Mar 01 07:45 PM
Miller EdwardSVP, Chief Compliance OfficerFeb 27Sale131.2026034,11215,214Mar 01 07:45 PM
O'Neill JulieEVP. Global OperationsFeb 27Sale131.20910119,39231,679Mar 01 07:46 PM
Wagner Heidi LSVP, Global Government AffairsFeb 27Sale131.2035846,97029,646Mar 01 07:44 PM
Carmichael ClareEVP, Chief HR OfficerFeb 27Sale131.20860112,83233,980Mar 01 07:44 PM
BELL LEONARDDirectorFeb 09Sale126.8424631,203394,648Feb 10 06:05 PM
Moriarty John BEVP & General CounselFeb 09Sale126.8416721,18246,476Feb 10 06:05 PM
MACKAY MARTINEVP & Global Head of R&DFeb 09Sale126.8421727,52439,743Feb 10 06:05 PM
Carmichael ClareEVP, Chief HR OfficerFeb 09Sale126.8416721,18234,840Feb 10 06:05 PM
Moriarty John BEVP & General CounselFeb 07Sale128.0913517,29246,643Feb 08 04:40 PM
Carmichael ClareEVP, Chief HR OfficerFeb 07Sale128.0916621,26335,007Feb 08 04:40 PM
BELL LEONARDDirectorFeb 07Sale128.091,010129,371394,894Feb 08 04:40 PM
Wagner Heidi LSVP, Global Government AffairsFeb 07Sale128.0922228,43630,004Feb 08 04:38 PM
Moriarty John BEVP & General CounselFeb 06Sale125.693,403427,73946,778Feb 08 04:40 PM
O'Neill JulieEVP. Global OperationsFeb 06Sale125.692,795351,30432,589Feb 08 04:40 PM
Carmichael ClareEVP, Chief HR OfficerFeb 06Sale125.703,404427,87235,173Feb 08 04:40 PM
MACKAY MARTINEVP & Global Head of R&DFeb 06Sale125.702,728342,90439,960Feb 08 04:39 PM
Thiel CarstenEVP, Chief Commercial OfficerFeb 06Sale125.6916520,73930,268Feb 08 04:39 PM
Miller EdwardSVP, Chief Compliance OfficerFeb 06Sale125.701,045131,35715,474Feb 08 04:39 PM
BELL LEONARDDirectorFeb 06Sale125.697,715969,728395,904Feb 08 04:40 PM
Wagner Heidi LSVP, Global Government AffairsFeb 06Sale125.691,710214,93530,226Feb 08 04:38 PM
BELL LEONARDDirectorJan 10Option Exercise22.901002,290403,719Jan 13 04:36 PM
BELL LEONARDDirectorJan 10Sale144.9910014,499403,619Jan 13 04:36 PM
BELL LEONARDDirectorJan 09Option Exercise22.904,853111,134408,472Jan 09 05:21 PM
BELL LEONARDDirectorJan 09Sale144.9033448,397403,285Jan 09 05:21 PM
BELL LEONARDDirectorJan 09Sale144.934,853703,345403,619Jan 09 05:21 PM
PARVEN ALVIN SDirectorJan 05Option Exercise54.2620,1661,094,30426,539Jan 09 05:21 PM
BELL LEONARDDirectorJan 05Option Exercise22.9034,210783,409438,497Jan 09 05:21 PM
BELL LEONARDDirectorJan 05Sale137.4066891,783403,619Jan 09 05:21 PM
BELL LEONARDDirectorJan 05Sale137.5334,2104,704,730404,287Jan 09 05:21 PM
PARVEN ALVIN SDirectorJan 05Sale136.862,493341,2023,880Jan 09 05:21 PM
PARVEN ALVIN SDirectorJan 05Sale138.5420,1662,793,7526,373Jan 09 05:21 PM
Moriarty John BEVP & General CounselDec 12Sale118.611,044123,82950,181Dec 13 06:24 PM
Thiel CarstenEVP, Chief Commercial OfficerDec 09Sale130.002,308300,04030,433Dec 13 06:24 PM
Wagner Heidi LSVP, Global Government AffairsNov 14Sale115.10596,79131,936Nov 16 06:00 PM
BELL LEONARDDirectorNov 04Option Exercise22.9036,649839,262440,936Nov 07 07:44 PM
BELL LEONARDDirectorNov 04Sale142.4066895,123404,287Nov 07 07:44 PM
BELL LEONARDDirectorNov 04Sale140.3436,6495,143,377404,287Nov 07 07:44 PM
BELL LEONARDDirectorOct 31Option Exercise22.901,30029,770406,589Nov 02 07:22 PM
BELL LEONARDDirectorOct 31Sale135.3733445,214404,955Nov 02 07:22 PM
BELL LEONARDDirectorOct 31Sale135.281,300175,864405,289Nov 02 07:22 PM
Thiel CarstenEVP, Chief Commercial OfficerOct 14Sale120.284,584551,36432,741Oct 18 06:29 PM
Wagner Heidi LSVP, Global Government AffairsOct 03Sale122.4112014,68931,995Oct 05 05:25 PM
Thiel CarstenEVP, Chief Commercial OfficerOct 03Sale122.41293,55037,325Oct 05 05:25 PM
Thiel CarstenEVP, Chief Commercial OfficerSep 13Sale129.003,000387,00037,354Sep 14 04:34 PM
Thiel CarstenEVP, Chief Commercial OfficerSep 12Sale124.2022527,94540,354Sep 14 04:34 PM
Miller EdwardSVP, Chief Compliance OfficerSep 09Sale128.3236747,09316,519Sep 09 06:23 PM
Thiel CarstenEVP, Chief Commercial OfficerSep 06Sale125.941,000125,94040,579Sep 08 04:33 PM
O'Neill JulieEVP. Global OperationsSep 02Sale126.2965082,08935,384Sep 02 05:11 PM
Carmichael ClareEVP, Chief HR OfficerAug 30Sale127.761,000127,76038,577Sep 01 04:57 PM
PARVEN ALVIN SDirectorAug 22Option Exercise18.0115,000270,15021,373Aug 24 05:33 PM
PARVEN ALVIN SDirectorAug 22Sale136.5315,0002,047,9506,373Aug 24 05:33 PM
PARVEN ALVIN SDirectorAug 15Sale135.5170094,8576,373Aug 24 05:33 PM
Carmichael ClareEVP, Chief HR OfficerAug 08Sale137.1416522,62839,577Aug 10 06:23 PM
Moriarty John BEVP & General CounselAug 08Sale137.1413518,51451,225Aug 10 06:23 PM
Sinha VikasEVP & CFOAug 08Sale137.1427737,988178,463Aug 10 06:23 PM
Wagner Heidi LSVP, Global Government AffairsAug 08Sale137.1422230,44532,115Aug 10 06:24 PM
BELL LEONARDDirectorAug 08Sale137.141,010138,511405,289Aug 10 06:22 PM
Hallal DavidCEOAug 08Sale137.1433245,530189,266Aug 10 06:22 PM
Moriarty John BEVP & General CounselJun 13Sale135.72918124,59151,360Jun 14 04:50 PM
MACKAY MARTINEVP & Global Head of R&DMay 16Sale139.204,097570,28442,688May 18 04:36 PM
Wagner Heidi LSVP, Global Government AffairsMay 13Sale138.65537,34832,337May 13 05:48 PM